RECOMBINANT TUMOR NECROSIS FACTOR-THYMOSIN-A1: THE IMPACT ON THE EFFECTIVENESS OF NEOADJUVANT CHEMOTHERAPY AND ANGIOGENESIS IN BREAST CANCER
The article covers the results of clinical application of a domestic drug based on recombinant tumor necrosis factor-alpha-thymosin-alpha1 (TNF-T) combined with chemotherapy FAC and РА during neoadjuvant treatment of patients with breast cancer IIB-IIIB stage. In contrast to the standard subcutaneous application method, the authors proposed peritumoral administration of TNF-T to maximize the drug's action directly on the tumor, peritumoral tissue. TNF-T 200000 IU peritumorally on days 1-5 of each treatment course showed significant increase in objective effect rate, including increase in frequency of complete regressions, and decrease in frequency and intensity of chemotherapy complications. Morphological examination revealed an increase rate of medical pathomorphosis grade III-IV, decreased number of microvessels in tumor in comparison with primary tumors